A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma

Completed

• Conditions: Renal Cell Carcinoma, Clear Cell

• Registration Number: NCT06656039
• Lead Sponsor: RenJi Hospital

Brief Summary

The main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of ccRCC patients by helping clinicians to formulate individualised follow-up and to screen for appropriate adjuvant therapy candidates.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-01
• Status Verified: 2024-10
• Primary Completion: 2024-10-10
• Study Completion: 2024-10-10
• Study First Submitted: 2024-10-20
• Study First Submitted QC: 2024-10-23
• Last Update Submitted: 2024-10-23
• Study First Posted: 2024-10-24
• Last Update Posted: 2024-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1200

Inclusion Criteria

• Patients with malignant renal tumours must have postoperative pathological confirmation of renal clear cell carcinoma with pathological TNM stage Ⅰ-Ⅲ;
• Have available preoperative imaging
• Have available post-operative pathological paraffin samples or HE-stained tissue sections
• Must agree to and be able to comply with the study's visit schedule and other requirements as specified in the protocol, including follow-up visits by telephone

Exclusion Criteria

• The patient's tumour type cannot be determined on the basis of histopathological sections
• Simultaneous combination of primary tumours at other sites;
• No regular follow-up imaging data
• Cases in which other factors led the investigator to believe that enrolment was inappropriate
• Cases that met all the inclusion criteria of the appeal and did not meet all the exclusion criteria were selected for this study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease free survival	"Baseline, immediately after the surgery", "Tumour recurrence or further follow-up", "Three months after surgery", "Six months after surgery", "Every year after surgery, at least follow-up 2years, up to 10 years"	Defined as from surgery to tumor recurrence or follow-up deadline

Trial Locations

Locations (1)

Renji Hospital; 🇨🇳 Shanghai, Shanghai, China